The Molecular Pathogenesis of Osteosarcoma: A Review

Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.

[1]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[2]  P. Choong,et al.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma , 2006, Clinical & Experimental Metastasis.

[3]  H. Takayanagi The Role of NFAT in Osteoclast Formation , 2007, Annals of the New York Academy of Sciences.

[4]  H. Koeffler,et al.  Alterations of the p53, Rb and MDM2 genes in osteosarcoma. , 1996, Journal of cancer research and clinical oncology.

[5]  L. Lau,et al.  The CCN family of angiogenic regulators: the integrin connection. , 1999, Experimental cell research.

[6]  K. Saja Regulation of Matrix Metalloproteinases , 2006 .

[7]  P. Choong,et al.  Osteosarcoma – conventional treatment vs. gene therapy , 2009, Cancer biology & therapy.

[8]  D. Campanacci,et al.  Expression of transforming growth factor β isoforms in osteosarcoma variants: association of tgfβ1 with high‐grade osteosarcomas , 1998 .

[9]  S. Friend,et al.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma , 1992 .

[10]  Jun Luo,et al.  The expression and significance of IDH1 and p53 in osteosarcoma , 2010, Journal of experimental & clinical cancer research : CR.

[11]  K. Hunter Ezrin, a key component in tumor metastasis. , 2004, Trends in molecular medicine.

[12]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[13]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[14]  Bin Wang,et al.  Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo , 2010, Molecular and Cellular Biochemistry.

[15]  S. Chakraborti,et al.  Regulation of matrix metalloproteinases: An overview , 2003, Molecular and Cellular Biochemistry.

[16]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[18]  Han-Soo Kim,et al.  RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[19]  Yong Zhang,et al.  Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population , 2011, Medical Oncology.

[20]  R. Langer,et al.  Troponin I is present in human cartilage and inhibits angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Wesolowski,et al.  M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase , 2003, Cell Death and Differentiation.

[22]  J. I. Phillips,et al.  Evidence against a role for SV40 in human mesothelioma. , 2005, Cancer research.

[23]  S. Hwang,et al.  Growth and development and other risk factors for osteosarcoma in children and young adults. , 1997, International journal of epidemiology.

[24]  M. Fernö,et al.  Urokinase‐plasminogen‐activator levels and prognosis in 69 soft‐tissue sarcomas , 1996, International journal of cancer.

[25]  Kozo Nakamura,et al.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system , 2005, Immunological reviews.

[26]  P. Houghton,et al.  Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts , 2010 .

[27]  S. Ferrari,et al.  Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  O. Fromigué,et al.  Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion* , 2008, Journal of Biological Chemistry.

[29]  Sanjiv Sam Gambhir,et al.  18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation , 2008, Cancer biology & therapy.

[30]  A. Uchida,et al.  Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. , 2003, Oncology reports.

[31]  F. Higashino,et al.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  G. Melino,et al.  Parathyroid hormone‐related protein confers chemoresistance by blocking apoptosis signaling via death receptors and mitochondria , 2009, International journal of cancer.

[33]  S. Coniglio,et al.  Rac1 Protects Epithelial Cells against Anoikis* , 2001, The Journal of Biological Chemistry.

[34]  E. T. Ek,et al.  Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis , 2007, Cancer Gene Therapy.

[35]  G. Castellani,et al.  Mechanisms of gene amplification and evidence of coamplification in drug‐resistant human osteosarcoma cell lines , 2009, Genes, chromosomes & cancer.

[36]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[37]  P. Choong,et al.  Osteosarcoma treatment: state of the art , 2009, Cancer and Metastasis Reviews.

[38]  R. Gutiérrez,et al.  Angiogenesis: an update. , 1994, Histology and histopathology.

[39]  C. Carman,et al.  Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.

[40]  S. de Jong,et al.  The insulin‐like growth factor system and sarcomas , 2009, The Journal of pathology.

[41]  L. Hofbauer,et al.  Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. , 1998, European journal of endocrinology.

[42]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Picci,et al.  C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.

[44]  P. Choong,et al.  Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway , 2008, Molecular Cancer Therapeutics.

[45]  F. Dutra,et al.  Osteosarcoma induced by beryllium oxide. , 1950, The American journal of pathology.

[46]  S. Cook,et al.  Extracellular Signal-regulated Kinases 1/2 Are Serum-stimulated “BimEL Kinases” That Bind to the BH3-only Protein BimEL Causing Its Phosphorylation and Turnover* , 2004, Journal of Biological Chemistry.

[47]  D. Fitzwilliams Popliteal Aneurysm , 1937, Proceedings of the Royal Society of Medicine.

[48]  Hisataka Yasuda,et al.  Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  F. Cogé,et al.  The role of the matrix metalloproteinases during in vitro vessel formation , 2004, Angiogenesis.

[50]  M. Dembo,et al.  Cell movement is guided by the rigidity of the substrate. , 2000, Biophysical journal.

[51]  P. Picci,et al.  Prognostic Value of CCN3 in Osteosarcoma , 2008, Clinical Cancer Research.

[52]  G. Ottaviani,et al.  The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.

[53]  K. Ishizaki,et al.  Mutation spectrum of the retinoblastoma gene in osteosarcomas. , 1994, Cancer research.

[54]  H. Saya,et al.  c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis , 2010, Oncogene.

[55]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[56]  D. Mercola,et al.  The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. , 1990, Oncogene.

[57]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[58]  Yong Zhang,et al.  Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.

[59]  D. Bar-Sagi,et al.  Redox-dependent downregulation of Rho by Rac , 2003, Nature Cell Biology.

[60]  S. Stoch,et al.  Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy , 2008, Clinical pharmacology and therapeutics.

[61]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[62]  M. Pearce,et al.  Stature of young people with malignant bone tumors , 2004, Pediatric blood & cancer.

[63]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[64]  A. Mazabraud [Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]. , 1975, Bulletin du cancer.

[65]  E. Ruoslahti,et al.  A Mitochondrial Protein, Bit1, Mediates Apoptosis Regulated by Integrins and Groucho/TLE Corepressors , 2005, Cell.

[66]  H. Dvorak,et al.  VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.

[67]  A. Greenspan,et al.  Differential Diagnosis in Orthopaedic Oncology , 2006 .

[68]  M. Takigawa,et al.  Effects of CTGF/Hcs24, a hypertrophic chondrocyte‐specific gene product, on the proliferation and differentiation of osteoblastic cells in vitro , 2000, Journal of cellular physiology.

[69]  T. Martin,et al.  Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. , 1988, The Journal of endocrinology.

[70]  H. Donninger,et al.  Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. , 2009, The American journal of pathology.

[71]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[72]  R. Khosravi‐Far,et al.  Regulation of tumor angiogenesis by thrombospondin-1. , 2006, Biochimica et biophysica acta.

[73]  A. Franchi,et al.  Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton , 1998, Virchows Archiv.

[74]  Sakae Tanaka,et al.  c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption , 1996, Nature.

[75]  A. Tsatsakis,et al.  Parathyroid hormone (PTH) peptides through the regulation of hyaluronan metabolism affect osteosarcoma cell migration , 2010, IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology.

[76]  M. Gebhardt,et al.  Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.

[77]  J. Zajac,et al.  Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106-01) cell line results in growth inhibition. , 2002, Bone.

[78]  G. Thurston,et al.  Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting , 2007, Proceedings of the National Academy of Sciences.

[79]  Stephen M Hewitt,et al.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.

[80]  A. Paulino,et al.  SECONDARY NEOPLASMS AFTER RADIOTHERAPY FOR A CHILDHOOD SOLID TUMOR , 2005, Pediatric hematology and oncology.

[81]  Carl W. Miller,et al.  Integration of SV40 in human osteosarcoma DNA , 1998, Oncogene.

[82]  M. Freedman,et al.  Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin , 2006, Cancer Gene Therapy.

[83]  F. Bertoni,et al.  Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. , 2004, Pathology, research and practice.

[84]  L. Helman,et al.  Autocrine Transforming Growth Factor-β Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein , 2000, Sarcoma.

[85]  P. Leavey,et al.  Lack of Prognostic Significance of Intratumoral Angiogenesis in Nonmetastatic Osteosarcoma , 2001, Journal of pediatric hematology/oncology.

[86]  A. Polednak Bone cancer among female radium dial workers. Latency periods and incidence rates by time after exposure: brief communication. , 1978, Journal of the National Cancer Institute.

[87]  H. Fujioka,et al.  Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. , 2006, Anticancer research.

[88]  M. Ladanyi,et al.  Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids , 2004, The Lancet.

[89]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[90]  H. Dvorak,et al.  Angiogenesis: update 2005 , 2005, Journal of thrombosis and haemostasis : JTH.

[91]  G. Bacci,et al.  Height as a risk factor in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Chirgwin,et al.  Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.

[93]  E. Engels Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research , 2005, Expert review of vaccines.

[94]  R. O’Keefe,et al.  Molecular biology and therapeutics in musculoskeletal oncology. , 2009, The Journal of bone and joint surgery. American volume.

[95]  David M. Thomas,et al.  RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer , 2007, Cancer and Metastasis Reviews.

[96]  A. Huvos,et al.  Over‐expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma , 2007, International journal of cancer.

[97]  Zhaoming Ye,et al.  Enhancement Effect of Adenovirus-Mediated Antisense c-myc and Caffeine on the Cytotoxicity of Cisplatin in Osteosarcoma Cell Lines , 2009, Chemotherapy.

[98]  E. Wagner,et al.  c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. , 1995, Cancer research.

[99]  Michael R. Green,et al.  Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome , 2007, Journal of Molecular Medicine.

[100]  P. Choong,et al.  Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. , 2009, Trends in molecular medicine.

[101]  A. Teti,et al.  Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. , 2008, Anti-cancer agents in medicinal chemistry.

[102]  P. Choong,et al.  Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours , 2010, Cancer Cell International.

[103]  S. Bielack,et al.  Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. , 2007, International journal of oncology.

[104]  Ak SharmaCol,et al.  Campbell's Operative Orthopaedics , 2004 .

[105]  Taro Matsumoto,et al.  Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. , 2006, Journal of atherosclerosis and thrombosis.

[106]  P. Choong,et al.  The pathophysiological role of PEDF in bone diseases. , 2010, Current molecular medicine.

[107]  J. Chirgwin,et al.  Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.

[108]  A. Togari,et al.  Osteoclast Differentiation Factor in Human Osteosarcoma Cell Line , 2000, Journal of immunoassay.

[109]  R. Kerbel,et al.  Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.

[110]  A. Sereno,et al.  Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response , 2010, Molecular Cancer Therapeutics.

[111]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[112]  F. Watt,et al.  Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis , 2004, The Journal of cell biology.

[113]  J. German Bloom's syndrome , 1995 .

[114]  M. Ladanyi,et al.  p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.

[115]  G. Watkins,et al.  Decreased Pigment Epithelium–Derived Factor Expression in Human Breast Cancer Progression , 2006, Clinical Cancer Research.

[116]  R. Monnat,et al.  Mutator phenotype of Werner syndrome is characterized by extensive deletions. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Carl W. Miller,et al.  Alterations of thep53, Rb andMDM2 genes in osteosarcoms , 2005, Journal of Cancer Research and Clinical Oncology.

[118]  J. Vandenbroucke,et al.  Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma , 2003, European Journal of Human Genetics.

[119]  J. Schlessinger New Roles for Src Kinases in Control of Cell Survival and Angiogenesis , 2000, Cell.

[120]  J. German,et al.  Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder , 2004, Chromosoma.

[121]  Kenneth M. Yamada,et al.  Cell–matrix adhesion , 2007, Journal of cellular physiology.

[122]  G. Bacci,et al.  Radiation-Induced Osteosarcoma Arising 20 years after the Treatment of Ewing's Sarcoma , 2003, Tumori.

[123]  S. Itohara,et al.  Contribution of host MMP‐2 and MMP‐9 to promote tumor vascularization and invasion of malignant keratinocytes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  M. Rosemann,et al.  Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma , 2010, Clinical Cancer Research.

[125]  N. Chandar,et al.  Inactivation of p53 gene in human and murine osteosarcoma cells. , 1992, British Journal of Cancer.

[126]  P. Choong,et al.  Localization of Pigment Epithelium-Derived Factor in Growing Mouse Bone , 2005, Calcified Tissue International.

[127]  E. T. Ek,et al.  PEDF‐derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[128]  P. Choong,et al.  The urokinase plasminogen activator receptor as a gene therapy target for cancer. , 2007, Trends in biotechnology.

[129]  J. Chirgwin,et al.  Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment , 2007, Journal of cellular biochemistry.

[130]  B. Fuchs,et al.  Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis , 2008, Molecular carcinogenesis.

[131]  H. S. Kim,et al.  The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma , 2000, International Orthopaedics.

[132]  P. Picci,et al.  Alteration of pRb/p16/cdk4 regulation in human osteosarcoma , 1999, International journal of cancer.

[133]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[135]  E. T. Ek,et al.  Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor , 2007, Clinical & Experimental Metastasis.